Pharmaceutical and Healthcare Products Consulting to Unlock Growth

pharmaceutical and healthcare industry image

Pharmaceutical and healthcare products consulting
Pharmaceutical and healthcare products consulting
Pharmaceutical and healthcare products consulting
Logo of a Midas' customer
Pharmaceutical and healthcare products consulting
Pharmaceutical and healthcare products consulting
Pharmaceutical and healthcare products consulting
Logo of a Midas' customer
Pharmaceutical and healthcare products consulting
Pharmaceutical and healthcare products consulting
Logo of a Midas' customer
Pharmaceutical and healthcare products consulting

Overcoming the “High-Cost” Access Barrier

Public health systems (like SUS or IMSS) and private insurers are increasingly restricting access to specialty drugs, citing budget sustainability. If you cannot translate your clinical trial data into a compelling economic narrative, you will face formulary exclusions or delayed payment

  • Our solution: Value propositions allow you to build robust pharmacoeconomic arguments that demonstrate the long-term savings of your therapy (e.g., reduced hospitalization), moving the conversation from price to value
  • Our solution: Win-Loss analysis uncovers the specific non-clinical reasons why a tender was lost or a molecule was rejected by a pharmacy and therapeutics (P&T) committee

Defending Against Aggressive Biosimilar Entry

The “patent cliff” in Latin America is steep. As exclusivity is lost, aggressive biosimilar competitors enter the market with deep discounts, threatening to erode your market share overnight. Reactive price cuts are often a losing battle

  • Our solution: Wargames allow your cross-functional teams (Medical, Access, Commercial) to simulate the launch of a competitor, testing your defense strategies and patient retention programs before the rival product hits the market
  • Our solution: Competitor analysis maps the pipelines and pricing strategies of incoming challengers, giving you the foresight to lock in long-term contracts before they arrive

Navigating Regulatory & Commercial Fragmentation

Assuming that a launch strategy for Brazil will work in Mexico or Colombia is a costly mistake. Divergent regulatory timelines (ANVISA vs. COFEPRIS) and distinct payer landscapes require hyper-local precision

  • Our solutions: Market analysis and market entry provide the granular regulatory and commercial intelligence needed to sequence your regional launches effectively, avoiding costly delays
  • Our solution: Strategy workshops align your local and regional teams on a unified Go-to-Market roadmap, ensuring that your global brand strategy adapts successfully to local realities

Because as former officers, directors and managers, we know firsthand the pressures of competing in the pharmaceutical and healthcare industries. Our experience means we understand your struggles and are ready to help you overcome them

Here’s what some of our clients have to say:

With more than 25 years dedicated to pharmaceutical and healthcare products consulting, we’ve partnered with some of the leading companies worldwide. And with an NPS of 82.2% (which is outstanding, given that anything above 70% is exceptional), you can trust we’ve made a real difference for our clients


Schedule a Call

In a brief teleconference, we’ll gather some basic information to prepare a customized proposal for you. Once you review and approve it, we’ll get started on your project

Receive Our Recommendations

We’ll keep you updated throughout the project with at least two key touchpoints:

The first one will share preliminary results, where we can fine-tune based on your specific needs

The second one will present our final recommendations

Achieve Success in the Market

With our expert recommendations, you’ll have the tools and strategies you need to thrive in the pharmaceutical and healthcare products industry

We’re ready when you are! Let’s work together to achieve your goals!